CompletedNCT00645320
Ziprasidone for psychosis after successful treatment in an earlier study
About this title
A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
Read the official source — NCT00645320Medication studyAges 18–55BrazilSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- RIO de Janeiro RJ and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 75
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Brazil
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00645320
- Official title
Show the full official title
An Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone
Get this study by email
Recruitment & locations
CompletedRIO de Janeiro RJ · Fortaleza · Salvador
5 more locations
- Belo Horizonte
- Curitiba
- Rio de Janeiro
- Jardim Santa Monica SN
- São Paulo
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone.
Who was this study for?
Listed age limits: 18 years to 55 years.
